Collagenase 3

[1]. V Knäuper, et al. Biochemical characterization of human collagenase-3. J Biol Chem. 1996 Jan 19;271(3):1544-50. [Content Brief]

[2]. A J Fosang, et al. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 1996 Feb 12;380(1-2):17-20. [Content Brief]

[3]. Chris De Savi, et al. Hydantoin based inhibitors of MMP13--discovery of AZD6605. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4705-12. [Content Brief]

[4]. Ann M Kennedy, et al. MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO). J Clin Invest. 2005 Oct;115(10):2832-42. [Content Brief]

[5]. Ekkehart Lausch, et al. Mutations in MMP9 and MMP13 determine the mode of inheritance and the clinical spectrum of metaphyseal anadysplasia. Am J Hum Genet. 2009 Aug;85(2):168-78. [Content Brief]

[6]. Lauren G Monovich, et al. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J Med Chem. 2009 Jun 11;52(11):3523-38. [Content Brief]

[7]. J M Freije, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994 Jun 17;269(24):16766-73. [Content Brief]

[8]. Laurent Devel, et al. Simple pseudo-dipeptides with a P2' glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins. J Biol Chem. 2012 Aug 3;287(32):26647-56. [Content Brief]

[9]. V Knäuper, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem. 1996 Jul 19;271(29):17124-31. [Content Brief]

[10]. Adam R Johnson, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem. 2007 Sep 21;282(38):27781-91. [Content Brief]

[11]. V Knäuper, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem. 1997 Mar 21;272(12):7608-16. [Content Brief]

[12]. Daniel P Becker, et al. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. J Med Chem. 2010 Sep 23;53(18):6653-80. [Content Brief]